-
Puncture Robotic Secures $13.9 Million in Series A+ Funding to Advance Medical Robotics
•
Puncture Robotic, a Shanghai-based developer of medical robots, has reportedly raised RMB 100 million (USD 13.9 million) in a Series A+ financing round. The round was led by Shenzhen Capital Group, with participation from Huayi Capital. The funds raised will be allocated towards product research and development, clinical validation, enhancement…
-
Sensview Secures Tens of Millions in Series A+ Funding for X-Ray Detector Tech
•
Sensview, a developer of solid-state imaging chips and detector module products based in Chengdu, has reportedly secured tens of millions of renminbi in a Series A+ financing round. The round was led by Matrix Partners, with contributions from Suzhou Industrial Park Zhongyuan Naxing Venture Capital and Leli Capital, as well…
-
Nanjing Enrui Kainuo Biotechnology Secures Pre-Series A Funding for Cell Therapy Development
•
Nanjing Enrui Kainuo Biotechnology Co., Ltd, a China-based cell therapy developer, has reportedly raised tens of millions of renminbi in a pre-Series A financing round. The round was led by Watere Capital, with participation from Future Invest. The funds raised will be directed towards IND filings, advancing the product pipeline,…
-
Pyrotech (Beijing) Biotechnology Secures $97.37 Million in Series A Financing
•
China-based biotech firm Pyrotech (Beijing) Biotechnology Co., Ltd announced the successful completion of a CNY 700 million (USD 97.37 million) Series A financing round last week. The round was spearheaded by SDIC Venture Capital, with China Venture Capital Fund as a co-leader. New participants in this funding round included China…
-
Shanghai Xinhengrui Medical Technology Secures Series A Funding for Heart Failure Device Development
•
Shanghai Xinhengrui Medical Technology Co., Ltd, a manufacturer of heart failure devices, has successfully raised close to RMB 100 million (USD 13.95 million) in a Series A financing round. The round was led by IDG Capital, with additional investments from Hygeia Capital and Everest Capital. The funds will be directed…
-
Beyond Therapeutics Secures Tens of Millions in Pre-Series A Financing for Ophthalmology and Oncology Pipeline
•
Beyond Therapeutics Co., Ltd., a biotechnology company based in Suzhou with a focus on ophthalmology and oncology, has reportedly raised tens of millions of renminbi in a Pre-Series A financing round. The round was led by Ming Bioventures, with contributions from Highpower Industrial and 3D BioOptima. The funds will be…
-
Centre Medical Secures Tens of Millions in Series A Financing to Expand Globally
•
Centre Medical, a Hong Kong-based cardiovascular specialized medical services provider, has reportedly raised tens of millions of US dollars in a Series A financing round. Lake Bleu Capital led the investment, with participation from Asia Pacific Medical Group. The funds will be directed towards the company’s globalization strategy, with a…
-
Guangdong’s OptoMedic Secures Over $27.8 Million in Pre-IPO Financing for Endoscopy Innovations
•
OptoMedic Technologies, Inc., a leading endoscopy specialist based in Guangdong, has reportedly raised upwards of RMB 200 million (USD 27.8 million) in a pre-IPO financing round. The round was led by CCB Private Equity Investment and Huajin Capital, with participation from Guoxin Capital and Befor Capital. The funds will be…
-
Sinopep-Allsino Bio Pharmaceutical Cuts Fundraising Target to RMB434 Million via Convertible Bonds”
•
Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd has revised its proposal for a convertible bond issuance, now expecting to raise RMB434 million, a decrease of RMB100 million compared to the initial target of RMB534 million set in November 2022. Proceeds Allocation for Strategic Projects and Working…
-
Jacobio Pharma Secures RMB 150 Million Investment to Advance Pipeline Programs
•
China-based Jacobio Pharma (HKG: 1167) has announced receiving RMB 150 million (USD 20.7 million) in funding from Beijing E-town International Investment & Development Co., Ltd. The investment is designated to support the research and development of the company’s pipeline programs, including the KRAS G12C-targeted glecirasib and other key projects. Jacobio’s…
-
ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion
•
China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to RMB 160 million (USD 22 million) through a private placement. The net proceeds from this capital increase are designated for Contract Development and Manufacturing Organization (CDMO) work on innovative peptide drugs, the industrialization of active…
-
Henlius Biotech Suspends IPO on STAR Market, Aims to Optimize Capital Strategy
•
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the suspension of its initial public offering (IPO) to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR), prioritizing capital market planning. The company assures that this decision will not affect its daily operations. Henlius initially planned to dual-list on the STAR…
-
Sinotau Pharmaceutical Secures Over RMB 1.1 Billion in Latest Financing Round
•
Sinotau Pharmaceutical Group, a prominent nuclear medicine (radiopharmaceutical) company headquartered in Beijing, has reportedly raised over RMB 1.1 billion (USD 150 million) in a new financing round. This capital influx is set to bolster the company’s research and development efforts, as well as the clinical application of diagnostic and therapeutic…
-
Cornerstone Robotics Secures RMB 800 Million in Funding for Surgical Robot Development
•
Cornerstone Robotics, a leading surgical robot developer based in Shenzhen, has reportedly raised RMB 800 million (USD 110 million) in its latest financing round. The investment was led by BridgeOne Capital and Lenovo Capital, with participation from existing investors Tsing Song Capital, Meituan LONG-Z, Qiming Venture Partners, Lilly Asia Ventures,…
-
Worg Pharmaceuticals Secures RMB 1.1 Billion in Series C Financing for Global Expansion
•
Worg Pharmaceuticals, a Hangzhou-based developer of allergy drugs, has reportedly raised RMB 1.1 billion (USD 152 million) in a Series C financing round. The funding was led by DT Capital, Baron Capital, YSIM Fund, Jiansu Private Equity Fund, Kequan Fund, and a European financial institute. The proceeds will be allocated…
-
Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share
•
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990), has priced its initial public offering (IPO) filing to the Hong Kong Stock Exchange at a range of HKD 60.6 to 72.8 per share. At an assumed offering price of HKD 60.60…
-
BDgene Technology Secures Over RMB 200 Million in Series B Financing Led by Lapam Capital
•
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has successfully raised over RMB 200 million (USD 27.7 million) in a Series B financing round. The round was led by Lapam Capital, with additional investments from Penglai Capital, Hermed Capital, Sunland Fund, and Sprinvest. The funds raised will be allocated towards…
